Significant improvements in FEV1 (MD, 0.11; 95% CI, 0.10 to 0.11), Asthma Control Questionnaire scores (MD, −0.20; 95% CI, −0.22 to −0.18), and annual exacerbation rates (MD, −0.15; 95% CI, −0.16 to −0.14) were also seen with anti–IL-4/IL-13 biologic therapies. This evidence concerns the gene IL4 and asthma.